RxDoctor Payments Data

Lisa Dornick

Family · Muncie, INNPI 1831789080

Payments from drug & device makers

$2,830in general payments, 2019–2025

Across 98 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Johnson & Johnson$359
  • Rochester Medical Corporation$191
  • Bayer$125
  • Astellas Pharma US Inc$101
  • Antares Pharma, Inc.$92
  • plus $868 from 21 others

What the payments were for

  • Travel & lodging$72626%
  • Food & beverage$2,01971%
  • Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,830 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$9,869
Medicare patients
76
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron31$25,386
GemtesaVibegron11$14,842
Tamsulosin Hcl186$2,840
Finasteride86$1,198
Solifenacin Succinate18$800
Duloxetine Hcl23$422
Alfuzosin Hcl ErAlfuzosin Hcl14$356
Gabapentin20$344
Pregabalin13$303
Oxycodone Hcl19$251
NitrofurantoinNitrofurantoin Macrocrystal14$227
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$203
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$152
Ciprofloxacin Hcl11$61
Meloxicam11$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$101$25,38631 claims
Sumitomo Pharma America, Inc.Gemtesa$14$14,84211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →